<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id><journal-id journal-id-type="iso-abbrev">Rheumatology (Oxford)</journal-id><journal-id journal-id-type="publisher-id">brheum</journal-id><journal-title-group><journal-title>Rheumatology (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">1462-0324</issn><issn pub-type="epub">1462-0332</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28968858</article-id><article-id pub-id-type="pmc">5722050</article-id><article-id pub-id-type="doi">10.1093/rheumatology/kex315</article-id><article-id pub-id-type="publisher-id">kex315</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject></subj-group></article-categories><title-group><article-title>Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis&#x02014;a proof of principle and exploratory trial: is dose tapering practical in good responders?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ibrahim</surname><given-names>Fowzia</given-names></name><xref ref-type="aff" rid="kex315-aff1">1</xref><!--<email>fowzia.ibrahim@kcl.ac.uk</email>--></contrib><contrib contrib-type="author"><name><surname>Lorente-C&#x000e1;novas</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="kex315-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dor&#x000e9;</surname><given-names>Caroline J</given-names></name><xref ref-type="aff" rid="kex315-aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bosworth</surname><given-names>Ailsa</given-names></name><xref ref-type="aff" rid="kex315-aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Margaret H</given-names></name><xref ref-type="aff" rid="kex315-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Galloway</surname><given-names>James B</given-names></name><xref ref-type="aff" rid="kex315-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cope</surname><given-names>Andrew P</given-names></name><xref ref-type="aff" rid="kex315-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pande</surname><given-names>Ira</given-names></name><xref ref-type="aff" rid="kex315-aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>David</given-names></name><xref ref-type="aff" rid="kex315-aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Scott</surname><given-names>David L</given-names></name><xref ref-type="aff" rid="kex315-aff1">1</xref></contrib></contrib-group><aff id="kex315-aff1">
<label>1</label>Academic Department of Rheumatology, Division of Immunology, Infection and Inflammatory Disease, Faculty of Life Sciences and Medicine, King's College London</aff><aff id="kex315-aff2">
<label>2</label>Comprehensive Clinical Trials Unit, University College London, London</aff><aff id="kex315-aff3">
<label>3</label>National Rheumatoid Arthritis Society, Maidenhead</aff><aff id="kex315-aff4">
<label>4</label>Rheumatology Department, Nottingham University Hospitals NHS Trust, Nottingham</aff><aff id="kex315-aff5">
<label>5</label>Musculoskeletal Services, Freeman Hospital, Newcastle, UK</aff><author-notes><corresp id="kex315-cor1"><label>*</label>Correspondence to: Fowzia Ibrahim, Academic Department of Rheumatology, Division of Immunology, Infection and Inflammatory Disease, Faculty of Life Sciences and Medicine, King&#x02019;s College London, Weston Education Centre, 10 Cutcombe Road, London SE5 9RJ, UK. E-mail: <email>fowzia.ibrahim@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-08-17"><day>17</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>8</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>56</volume><issue>11</issue><fpage>2004</fpage><lpage>2014</lpage><history><date date-type="received"><day>15</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>12</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/" license-type="cc-by"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="kex315.pdf"/><abstract><title>Abstract</title><sec><title>Objectives</title><p>RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response.</p></sec><sec><title>Methods</title><p>We enrolled RA patients receiving etanercept or adalimumab and a DMARD with DAS28 under 3.2 for over 3 months. Initially (months 0&#x02013;6) patients were randomized to control (constant TNFi) or two experimental groups (tapering TNFi by 33 or 66%). Subsequently (months 6&#x02013;12) control subjects were randomized to taper TNFi by 33 or 66%. Disease flares (DAS28 increasing &#x02a7e;0.6 with at least one additional swollen joint) were the primary outcome.</p></sec><sec><title>Results</title><p>Two hundred and forty-four patients were screened, 103 randomized and 97 treated. In months 0&#x02013;6 there were 8/50 (16%) flares in controls, 3/26 (12%) with 33% tapering and 6/21 (29%) with 66% tapering. Multivariate Cox analysis showed time to flare was unchanged with 33% tapering but was reduced with 66% tapering compared with controls (adjusted hazard ratio 2.81, 95% CI: 0.99, 7.94; P = 0.051). Analysing all tapered patients after controls were re-randomized (months 6&#x02013;12) showed differences between groups: there were 6/48 (13%) flares with 33% tapering and 14/39 (36%) with 66% tapering. Multivariate Cox analysis showed 66% tapering reduced time to flare (adjusted hazard ratio 3.47, 95% CI: 1.26, 9.58; P = 0.016).</p></sec><sec><title>Conclusion</title><p>Tapering TNFi by 33% has no impact on disease flares and appears practical in patients in sustained remission and low disease activity states.</p></sec><sec><title>Trail registration</title><p>EudraCT, <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</ext-link>, 2010-020738-24; ISRCTN registry, <ext-link ext-link-type="uri" xlink:href="https://www.isrctn.com">https://www.isrctn.com</ext-link>, 28955701</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>TNF</kwd><kwd>RA</kwd><kwd>biologics</kwd><kwd>tapering</kwd><kwd>interruption treatment</kwd><kwd>flare</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Arthritis Research UK</named-content><named-content content-type="funder-identifier">10.13039/501100000341</named-content></funding-source><award-id>18813</award-id></award-group></funding-group><counts><page-count count="11"/></counts></article-meta></front><body><p>
<boxed-text id="kex315-BOX1" position="float" orientation="portrait"><caption><p>Rheumatology key messages</p></caption><list list-type="bullet"><list-item><p>Tapering TNF inhibitors in RA patients by 33% over 6 months did not reduce time to disease flare.</p></list-item><list-item><p>By 12 months, 45% of RA patients who tapered TNF inhibitor treatment were able to stop it entirely.</p></list-item></list></boxed-text>
</p><sec sec-type="intro"><title>Introduction</title><p>Trials and observational studies underpinning the regulatory approval of TNF inhibitors (TNFi) for treating RA patients focus on initial efficacy and long-term safety [<xref rid="kex315-B1" ref-type="bibr">1&#x02013;3</xref>]. What to do after achieving disease control is another question. Currently doses of TNFi effective in inducing responses in active RA are continued to maintain control, despite limited evidence they are needed. Maintaining disease control maintained with lower doses of TNFi should increase their cost-effectiveness.</p><p>The Optimizing Treatment with TNFi in RA (OPTTIRA) trial was designed when there was limited information about tapering TNF inhibitor in RA patients with good treatment responses. Subsequently several observational studies and trials evaluated tapering. Systematic reviews of reports before 2015 [<xref rid="kex315-B4" ref-type="bibr">4&#x02013;7</xref>] found evidence supporting TNF tapering. The Cochrane systematic review, which focused exclusively on trials [<xref rid="kex315-B7" ref-type="bibr">7</xref>], found tapering gave similar outcomes to continuing standard doses of adalimumab and etanercept; complete discontinuation increased flares. Another seven trials [<xref rid="kex315-B8" ref-type="bibr">8&#x02013;14</xref>] were published after these systematic reviews were completed. One trial [<xref rid="kex315-B12" ref-type="bibr">12</xref>] concluded disease activity guided adalimumab or etanercept dose reductions were non-inferior to usual care for major flares; dose reduction or stopping was possible in two-thirds of patients. Overall the evidence suggests tapering does not substantially increase flares; stopping completely may do so. Recent observational studies support dose reduction [<xref rid="kex315-B15" ref-type="bibr">15&#x02013;17</xref>]. Reviews by Schett <italic>et al.</italic> [<xref rid="kex315-B18" ref-type="bibr">18</xref>] and Edwards <italic>et al.</italic> [<xref rid="kex315-B19" ref-type="bibr">19</xref>] highlighted the importance of TNF inhibitor tapering and minimizing other long-term DMARDs. However, there remain uncertainties about which patients should have their TNFi tapered and whether all tapering regimens are similar.</p><p>OPTTIRA is a randomized trial evaluating two tapering regimens in RA. It recruited patients showing EULAR good responses to TNFi [<xref rid="kex315-B20" ref-type="bibr">20</xref>] and compared tapering with continuing standard doses. Tapering regimens reduced doses to one-third and two-thirds initial response induction doses of adalimumab or etanercept over 6 months. OPTTIRA also examined subsequently stopping TNFi completely. It used time to flare to assess the effects of TNF inhibitor tapering. Flares occurred when the DAS28 joints was over 3.2 and increased by 0.6 or more.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Design</title><p>OPTTIRA was an open label, 6-month multicentre proof of principle trial with a subsequent 6-month exploratory phase for patients who completed the initial trial. OPTTIRA enrolled RA patients achieving good responses [<xref rid="kex315-B20" ref-type="bibr">20</xref>] with low disease activity or remission taking standard TNFi doses and receiving one or more DMARDs.</p></sec><sec sec-type="subjects"><title>Participants</title><p>Patients receiving TNFi had met existing English criteria from the National Institute for Health and Clinical Excellence for these agents. The criteria have changed with time; they included failing to respond to MTX and another DMARD [<xref rid="kex315-B21" ref-type="bibr">21</xref>]. These criteria meant all patients had established RA. Patients had also achieved sustained good responses with DAS28 scores of &#x02a7d;3.2 without increases of &#x0003e; 0.6 during the previous 3 months.</p></sec><sec><title>Interventions</title><p>Patients were taking etanercept or adalimumab; their existing TNFi were the trial investigational medicinal products.</p><p>The proof of principle trial (months 0&#x02013;6) compared three groups: experimental group 1: TNF inhibitor tapered by 33% initial dose; experimental group 2: TNF inhibitor tapered by 66% initial dose; control group: continued standard doses. <xref ref-type="supplementary-material" rid="sup1">Supplementary Tables S1 and S2</xref>, available at <italic>Rheumatology</italic> Online, show reducing etanercept and adalimumab dosing schedules.</p><p>In the exploratory phase (months 7&#x02013;12) patients in experimental groups increased times between injections until they stopped. Patients in the control group were further randomized into two groups: control group A had TNFi tapered by 33% initial dose; control group B had TNFi tapered by 66% initial dose. <xref ref-type="supplementary-material" rid="sup1">Supplementary Tables S3 and S4</xref>, available at <italic>Rheumatology</italic> Online, show the dosing schedules. The tapering schedules reflected standard dosing regimens related to the half-lives of the drugs.</p></sec><sec><title>Primary outcome</title><p>The primary outcome was time to first flare, defined as an increase in DAS28 scores &#x02a7e;0.6 resulting in a DAS28 &#x0003e;3.2 together with an increase in the swollen joint count; both had to be present on two occasions at least 1 week apart. An increase in DAS28 score &#x02a7e;1.2 resulting in DAS28 &#x0003e;3.2 was defined as flare irrespective of changes in swollen joints. These criteria reflect the subsequently developed DAS28 flare definitions proposed by OMERACT [<xref rid="kex315-B22" ref-type="bibr">22</xref>] and supported by the Cochrane group [<xref rid="kex315-B7" ref-type="bibr">7</xref>]. Patients were assessed 3 monthly and telephoned by their Research Nurse monthly to check their disease control. Patients who considered they were experiencing a flare were seen urgently (within 2 weeks).</p></sec><sec><title>Secondary outcomes</title><p>HAQ, EuroQol 5-dimension scale (EQ5D-3L), Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Functional Assessment of Chronic Illness Therapy were assessed at 0, 3, 6 and 12 months. X-rays of the hands (including wrists) and feet were taken at 0, 6 and 12 months with digitized X-rays read by an experienced observer (D.L.S.) blinded to treatment using modified Larsen scores. Every 3 months disease activity assessments recorded tender and swollen joint counts (28 joints), ESR, patients&#x02019; global assessments of disease activity (100 mm visual analogue scale) and DAS for 28 joints together with details of medication and adverse effects. An anonymized electronic data capture system collected clinical data except X-rays (<ext-link ext-link-type="uri" xlink:href="http://www.medscinet.net">http://www.medscinet.net</ext-link>).</p></sec><sec><title>Sample size</title><p>The TEMPO trial showed 15% of patients on etanercept with MTX withdrew annually (flares and other problems) [<xref rid="kex315-B23" ref-type="bibr">23</xref>, <xref rid="kex315-B24" ref-type="bibr">24</xref>]. The BSR Biologics Register [<xref rid="kex315-B25" ref-type="bibr">25</xref>] showed 12% of patients withdraw annually from TNFi. These results suggested 12&#x02013;15% of patients taking TNFi flared annually; during the 6 months proof of principle trial the likelihood of flare was 7.5%. Studying 30 patients in one tapering group would show a significant difference at the 5% level with 80% power if over 42% of patients flared; such a difference would mean tapering was not clinically useful. Therefore a proof of principle study of 30 patients in each group should provide sufficient information to reject the concept if it is clearly ineffective, as well as giving enough data to design larger trials if needed. We allowed for 10% of patients not continuing in the trial and therefore aimed to recruit 33 patients in each group with a total study size of 99 patients.</p><p>The randomization algorithm considered patients in both proof of principle trial and the exploratory study taking different biologics. Consequently the randomization ratio generated was 1:1:2; we recruited twice as many to the control group than the initial tapering groups in the proof of principle trial.</p></sec><sec><title>Randomization</title><p>Potentially eligible patients were screened and reasons for non-entry recorded. The electronic data capture system (MedSciNet) randomized patients using minimization into experimental and control groups, stratified by TNF inhibitor (etanercept or adalimumab) using randomly permuted blocks. Recruiting staff were blinded to allocation sequences.</p></sec><sec><title>Blinding</title><p>OPTTIRA was unblinded for assessors because it used treatment-specific algorithms with the adjustment of multiple dosing intervals of the drugs. Disability and quality of life were assessed by patients and X-ray reading was blinded.</p></sec><sec sec-type="methods"><title>Statistical methods</title><p>Randomized patients accepting their allocated treatment were analysed on an intention-to-treat basis. Data management and analyses used Stata (version 14.0, StataCorp, College Station, TX, USA). Baseline characteristics were summarized by randomization group as means and standard deviations (normally distributed variables), medians and interquartile ranges (non-normally distributed variables) and frequencies and percentages (categorical variables). Serious adverse event rates in each arm were compared with controls.</p><p>Separate analysis was performed for the proof of principle phase (0&#x02013;6 months) and the exploratory phase (6&#x02013;12 months). The primary outcome was time to flare (months) for patients randomized to control, 33% taper or 66% taper, defined as the time from study entry to the first flare. Patients without flares, who withdrew or were lost to follow-up, were censored at the time of their last visit. Eight out of 97 patients were lost to follow-up (<xref ref-type="supplementary-material" rid="sup2">supplementary Fig. S1</xref>, available at <italic>Rheumatology</italic> Online). Kaplan&#x02013;Meier curves and the log-rank test compared randomized groups. Survival analysis analysed time to flare. The validity of the assumption of proportionality required for Cox regression was investigated graphically (using Nelson&#x02013;Aalen plots) as well as using Schoenfeld residuals in the final Cox models.</p><p>Secondary outcomes were analysed using mixed models to estimate treatment effects including baseline values as covariates. Working correlation matrices were unstructured, which is not unduly restrictive given that measurements are only taken at three time points. The sandwich estimator of covariance matrix was used in order to obtain appropriate (consistent) estimates of precision. All P-values were two sided.</p></sec><sec><title>Ethical review</title><p>The North West London Research Ethics Committee approved OPTTIRA (REC Ref: 10/H0720/69). All enrolled patients gave written informed consent. The trial was registered with the UK Clinical Research Network and other relevant organizations (EudraCT number: 2010-020738-24; ISRCTN: 28955701).</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="subjects"><title>Patients and treatments</title><sec><title>Recruitment</title><p>Between April 2011 and June 2013, 244 patients were screened, 103 randomized and 97 accepted their allocated treatment (<xref ref-type="supplementary-material" rid="sup2">supplementary Fig. S1</xref>, available at <italic>Rheumatology</italic> Online).</p></sec><sec><title>Treatment at baseline</title><p>All patients received disease modifying drugs: 82 had DMARD monotherapy; 15 received combination DMARDs. The DMARDs comprised MTX (81 patients), HCQ (18), SSZ (11) and LEF (4). All patients received etanercept (43 patients) or adalimumab (54). Two patients were taking prednisolone. The mean baseline treatment duration was 5.8 years (range 0.5&#x02013;15.1 years).</p></sec><sec><title>Proof of principle phase</title><p>Of the patients, 50/97 were randomized to continue biologic at unchanged dosages, 26/97 to taper biologics by 33% and 21/97 to taper by 66%; 74/97 patients completed 6 months&#x02019; treatment, 8/97 were lost to follow-up and 15/97 discontinued tapering but were followed up; 13/97 patients stopped treatment for flares, 1/97 stopped for drug toxicity and 9/97 stopped for other reasons including 1/97 for disease progression and 5/97 at the patients&#x02019; own request.</p></sec><sec><title>Exploratory phase</title><p>Of the patients randomized to continue biologics at unchanged doses who completed the 6-month proof of principle trial, 40/50 were re-randomized in the exploratory phase: 22/40 tapered by 33% and 18/40 tapered by 66%; 32/40 patients completed 6 months&#x02019; treatment and 8/40 patients discontinued tapering but were followed up; 5/40 stopped treatment for flares, 2/40 had disease progression and 1/40 stopped at the patients&#x02019; own request.</p><p>The 34 patients who had tapered for 6 months and continued on the treatment schedule in the proof of principle trial tapered further until their biologics were completely stopped by 6 months; 21/34 completed 6 months&#x02019; treatment, 2/34 were lost to follow-up and 11/34 discontinued tapering but were followed up. All 13/34 patients stopping treatment did so because of flares.</p></sec><sec><title>Baseline data and numbers analysed</title><p>Demographic and disease assessments were similar in all patient groups (<xref ref-type="table" rid="kex315-T1">Table 1</xref>). The patients had established RA (median disease duration 11.3 years) with low DAS28-ESR (median 2.0) and low HAQ scores (median 0.50). All treated patients were analysed in the proof of principle trial.
<table-wrap id="kex315-T1" orientation="portrait" position="float"><label>T<sc>able</sc> 1</label><caption><p>Baseline demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead align="left"><tr><th rowspan="2" colspan="1"/><th rowspan="1" colspan="1">33% tapering</th><th rowspan="1" colspan="1">66% tapering</th><th rowspan="1" colspan="1">Controls</th><th rowspan="1" colspan="1">Total</th></tr><tr><th rowspan="1" colspan="1">n = 26</th><th rowspan="1" colspan="1">n = 21</th><th rowspan="1" colspan="1">n = 50</th><th rowspan="1" colspan="1">n = 97</th></tr></thead><tbody align="left"><tr><td colspan="5" rowspan="1">Demographic variables</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Age, mean (<sc>s</sc>.<sc>d</sc>.), years</td><td rowspan="1" colspan="1">59 (11)</td><td rowspan="1" colspan="1">58 (9)</td><td rowspan="1" colspan="1">56 (12)</td><td rowspan="1" colspan="1">57 (11)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Height, mean (<sc>s</sc>.<sc>d</sc>.), m</td><td rowspan="1" colspan="1">1.66 (0.08)</td><td rowspan="1" colspan="1">1.67 (0.08)</td><td rowspan="1" colspan="1">1.66 (0.09)</td><td rowspan="1" colspan="1">1.66 (0.08)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Weight, mean (<sc>s</sc>.<sc>d</sc>.), kg</td><td rowspan="1" colspan="1">74.8 (15.6)</td><td rowspan="1" colspan="1">70.1 (14.4)</td><td rowspan="1" colspan="1">74.3 (16.1)</td><td rowspan="1" colspan="1">73.5 (15.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;BMI, kg/m<sup>2</sup></td><td rowspan="1" colspan="1">26.9 (21.9&#x02013;31.6)</td><td rowspan="1" colspan="1">24.5 (22.6&#x02013;27.8)</td><td rowspan="1" colspan="1">25.3 (23.1&#x02013;29.7)</td><td rowspan="1" colspan="1">25.4 (22.6&#x02013;29.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Disease duration, years</td><td rowspan="1" colspan="1">11.2 (6.2&#x02013;19.0)</td><td rowspan="1" colspan="1">10.6 (7.3&#x02013;15.9)</td><td rowspan="1" colspan="1">11.9 (7.3&#x02013;16.7)</td><td rowspan="1" colspan="1">11.3 (7.3&#x02013;16.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Female gender, n (%)</td><td rowspan="1" colspan="1">19 (73)</td><td rowspan="1" colspan="1">15 (71)</td><td rowspan="1" colspan="1">38 (76)</td><td rowspan="1" colspan="1">72 (74)</td></tr><tr><td colspan="5" rowspan="1">&#x02003;Smoking status, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Ex</td><td rowspan="1" colspan="1">9 (43)</td><td rowspan="1" colspan="1">7 (41)</td><td rowspan="1" colspan="1">16 (35)</td><td rowspan="1" colspan="1">32 (38)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;Current</td><td rowspan="1" colspan="1">2 (9)</td><td rowspan="1" colspan="1">3 (18)</td><td rowspan="1" colspan="1">7 (15)</td><td rowspan="1" colspan="1">12 (14)</td></tr><tr><td colspan="5" rowspan="1">Clinical variables</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Tender joint counts, 28 joints</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;1.00)</td><td rowspan="1" colspan="1">0 (0&#x02013;1.00)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Swollen joint counts, 28 joints</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Tender joint counts, 68 joints</td><td rowspan="1" colspan="1">0 (0&#x02013;1.00)</td><td rowspan="1" colspan="1">0 (0&#x02013;2.00)</td><td rowspan="1" colspan="1">0 (0&#x02013;2.00)</td><td rowspan="1" colspan="1">0 (0&#x02013;2.00)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Swollen joint counts, 66 joints</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td><td rowspan="1" colspan="1">0 (0&#x02013;0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;ESR, mm/h</td><td rowspan="1" colspan="1">6 (4&#x02013;24)</td><td rowspan="1" colspan="1">8 (4&#x02013;19)</td><td rowspan="1" colspan="1">9 (5&#x02013;20)</td><td rowspan="1" colspan="1">8 (5&#x02013;19)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;CRP, mg/l</td><td rowspan="1" colspan="1">5 (2&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;5)</td><td rowspan="1" colspan="1">5 (2&#x02013;7)</td><td rowspan="1" colspan="1">5 (2&#x02013;6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Assessor global rating, mm</td><td rowspan="1" colspan="1">3 (0&#x02013;10)</td><td rowspan="1" colspan="1">4 (1&#x02013;10)</td><td rowspan="1" colspan="1">3 (1&#x02013;9)</td><td rowspan="1" colspan="1">3 (1&#x02013;10)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Patient global assessment, mm</td><td rowspan="1" colspan="1">9 (1&#x02013;15)</td><td rowspan="1" colspan="1">4 (1&#x02013;16)</td><td rowspan="1" colspan="1">5 (2&#x02013;16)</td><td rowspan="1" colspan="1">5 (1&#x02013;16)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;DAS28 ESR</td><td rowspan="1" colspan="1">1.7 (1.1&#x02013;2.6)</td><td rowspan="1" colspan="1">1.9 (1.3&#x02013;2.6)</td><td rowspan="1" colspan="1">2.1 (1.4&#x02013;2.6)</td><td rowspan="1" colspan="1">2.0 (1.3&#x02013;2.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;DAS28 CRP</td><td rowspan="1" colspan="1">2.3 (2.0&#x02013;2.5)</td><td rowspan="1" colspan="1">2.2 (1.7&#x02013;2.5)</td><td rowspan="1" colspan="1">2.1 (1.9&#x02013;2.5)</td><td rowspan="1" colspan="1">2.2 (1.9&#x02013;2.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;HAQ</td><td rowspan="1" colspan="1">0.75 (0.13&#x02013;1.38)</td><td rowspan="1" colspan="1">0.38 (0.0&#x02013;0.88)</td><td rowspan="1" colspan="1">0.50 (0.13&#x02013;1.50)</td><td rowspan="1" colspan="1">0.50 (0.13&#x02013;1.38)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;EQ5D-3L</td><td rowspan="1" colspan="1">0.79 (0.66&#x02013;1.00)</td><td rowspan="1" colspan="1">0.80 (0.69&#x02013;1.00)</td><td rowspan="1" colspan="1">0.74 (0.59&#x02013;1.00)</td><td rowspan="1" colspan="1">0.76 (0.66&#x02013;1.00)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pain visual analogue score, mm</td><td rowspan="1" colspan="1">6 (1&#x02013;10)</td><td rowspan="1" colspan="1">8 (1&#x02013;19)</td><td rowspan="1" colspan="1">5 (0&#x02013;25)</td><td rowspan="1" colspan="1">5 (1&#x02013;19)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;FACIT Fatigue Scale</td><td rowspan="1" colspan="1">40 (31&#x02013; 45)</td><td rowspan="1" colspan="1">41 (35&#x02013;46)</td><td rowspan="1" colspan="1">42 (36&#x02013;46)</td><td rowspan="1" colspan="1">41 (35&#x02013;46)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Larsen score</td><td rowspan="1" colspan="1">33 (12&#x02013;76)</td><td rowspan="1" colspan="1">34 (17&#x02013;63)</td><td rowspan="1" colspan="1">66 (29&#x02013;89)</td><td rowspan="1" colspan="1">51 (16&#x02013;82)</td></tr><tr><td colspan="5" rowspan="1">&#x02003;SF-36</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;PCS</td><td rowspan="1" colspan="1">43 (38&#x02013;51)</td><td rowspan="1" colspan="1">46 (37&#x02013;51)</td><td rowspan="1" colspan="1">44 (32&#x02013;52)</td><td rowspan="1" colspan="1">45 (34&#x02013;52)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;MCS</td><td rowspan="1" colspan="1">51 (43&#x02013;58)</td><td rowspan="1" colspan="1">57 (48&#x02013;60)</td><td rowspan="1" colspan="1">58 (52&#x02013;61)</td><td rowspan="1" colspan="1">57 (49&#x02013;60)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Values shown as median (interquartile range) unless otherwise stated. EQ5D-3L: EuroQol 5-dimension scale; FACIT: Functional Assessment of Chronic Illness Therapy; MCS: mental health summary score; PCS: physical health summary score; SF-36: 36-Item Short Form Health Survey.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec><title>Primary outcome</title><sec><title>Proof of principle phase</title><p>Seventeen patients flared comprising 8/50 (16%) control patients, 3/26 (12%) patients tapering by 33% and 6/21 (29%) patients tapering by 66% (<xref ref-type="table" rid="kex315-T2">Table 2</xref>). Univariate and multivariate Cox analysis of the intention to treat population (<xref ref-type="table" rid="kex315-T2">Table 2</xref>) showed no evidence 33% tapering reduced time to flare (adjusted hazard ratio 0.87, 95% CI: 0.22, 3.88; P = 0.835), but 66% tapering significantly reduced time to flare compared with controls (adjusted hazard ratio 2.81, 95% CI: 0.99, 7.94; P = 0.051). <xref ref-type="fig" rid="kex315-F1">Figure 1</xref> shows Kaplan&#x02013;Meier survival curves comparing groups.
<table-wrap id="kex315-T2" orientation="portrait" position="float"><label>T<sc>able</sc> 2</label><caption><p>Flare rates and univariate and multivariate cox analyses in intention to treat analysis and exploratory studies</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/></colgroup><thead align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Flares, n (%)</th><th colspan="2" align="center" rowspan="1">Unadjusted</th><th colspan="2" align="center" rowspan="1">Adjusted<xref ref-type="table-fn" rid="tblfn2"><sup>a</sup></xref></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">HR (95% CI)</th><th rowspan="1" colspan="1">P-value</th><th rowspan="1" colspan="1">HR (95% CI)</th><th rowspan="1" colspan="1">P-value</th></tr></thead><tbody align="left"><tr><td rowspan="3" colspan="1">Intention to treat analysis (n = 97)</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">8/50 (16)</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">33% tapering</td><td rowspan="1" colspan="1">3/26 (12)</td><td rowspan="1" colspan="1">0.90 (0.23, 3.48)</td><td rowspan="1" colspan="1">0.873</td><td rowspan="1" colspan="1">0.87 (0.22, 3.88)</td><td rowspan="1" colspan="1">0.835</td></tr><tr><td rowspan="1" colspan="1">66% tapering</td><td rowspan="1" colspan="1">6/21 (29)</td><td rowspan="1" colspan="1">2.52 (0.85, 7.48)</td><td rowspan="1" colspan="1">0.097</td><td rowspan="1" colspan="1">2.81 (0.99, 7.94)</td><td rowspan="1" colspan="1">0.051</td></tr><tr><td rowspan="2" colspan="1">Exploratory study (n = 40)</td><td rowspan="1" colspan="1">33% tapering</td><td rowspan="1" colspan="1">3/22 (14)</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">66% tapering</td><td rowspan="1" colspan="1">8/18 (44)</td><td rowspan="1" colspan="1">4.16 (1.08, 15.99)</td><td rowspan="1" colspan="1">0.038</td><td rowspan="1" colspan="1">5.10 (1.18, 21.95)</td><td rowspan="1" colspan="1">0.029</td></tr><tr><td rowspan="2" colspan="1">Combined tapering (n = 87)</td><td rowspan="1" colspan="1">33% tapering</td><td rowspan="1" colspan="1">6/48 (13)</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">66% tapering</td><td rowspan="1" colspan="1">14/39 (36)</td><td rowspan="1" colspan="1">3.29(1.26, 8.63)</td><td rowspan="1" colspan="1">0.015</td><td rowspan="1" colspan="1">3.47(1.26, 9.58)</td><td rowspan="1" colspan="1">0.016</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>a</label><p>The multivariate model was adjusted for age at registration, gender and disease duration.</p></fn></table-wrap-foot></table-wrap></p><fig id="kex315-F1" orientation="portrait" position="float"><label>F<sc>ig</sc>. 1</label><caption><p>Kaplan&#x02013;Meier curves for intention to treat analysis, exploratory and combined tapering groups</p></caption><graphic xlink:href="kex315f1"/></fig></sec><sec sec-type="subjects"><title>Exploratory phase&#x02014;re-randomized patients</title><p>Eleven patients flared: 3/22 (14%) patients tapering by 33% and 8/18 (44%) tapering by 66% (<xref ref-type="table" rid="kex315-T2">Table 2</xref>). Univariate and multivariate Cox analysis showed 66% tapering significantly increased the risk of flare compared with 33% tapering (adjusted hazard ratio 5.10, 95% CI: 1.81, 21.95; P = 0.029).</p><sec><title>Combined tapering groups</title><p>Results from re-randomized initial controls were combined with the tapering groups in the proof of principle trial to provide a detailed comparison of time to flare in the two tapering regimens over 6 months. Six of forty-eight (13%) patients tapering by 33% flared compared with 14/39 (36%) patients tapering by 66% (<xref ref-type="table" rid="kex315-T2">Table 2</xref>). Multivariate Cox analysis showed 66% tapering significantly increased the risk of flare compared with 33% tapering (adjusted hazard ratio 3.47, 95% CI: 1.26, 9.58; P = 0.016).</p></sec></sec></sec><sec><title>Secondary outcomes in proof of principle trial</title><p>Longitudinal analysis of changes within the first 6 months in all treated patients (<xref ref-type="table" rid="kex315-T3">Table 3</xref>) showed little evidence that 33% tapering had any impact on clinical or functional assessments. However, 66% tapering led to significant worsening in tender and swollen joint counts, C-reactive protein levels and ESR and DAS28 ESR but not DAS28 CRP scores. An interesting finding is that patient related outcome measures including patient global score, HAQ, EQ5D-3L, visual analogue scale (VAS) pain and functional assessment of chronic illness therapy fatigue scores were unaffected by tapering, including tapering by 66%. Assessor global scores and Larsen scores also did not differ between groups. Details of secondary outcomes are shown in <xref ref-type="supplementary-material" rid="sup1">supplementary Table S5</xref>, available at <italic>Rheumatology</italic> Online.
<table-wrap id="kex315-T3" orientation="portrait" position="float"><label>T<sc>able</sc> 3</label><caption><p>Secondary outcomes for the effect of randomized treatment arm in longitudinal analysis for first 6 months</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead align="left"><tr><th rowspan="1" colspan="1">Outcome</th><th colspan="4" align="center" rowspan="1">33% tapering</th><th colspan="4" align="center" rowspan="1">66% tapering</th></tr><tr><th rowspan="2" colspan="1"/><th rowspan="1" colspan="1">Unadjusted coefficient</th><th rowspan="2" colspan="1">P-value</th><th rowspan="1" colspan="1">Adjusted coefficient<xref ref-type="table-fn" rid="tblfn3"><sup>a</sup></xref></th><th rowspan="2" colspan="1">P-value</th><th rowspan="1" colspan="1">Unadjusted coefficient</th><th rowspan="2" colspan="1">P-value</th><th rowspan="1" colspan="1">Adjusted coefficient<xref ref-type="table-fn" rid="tblfn3"><sup>a</sup></xref></th><th rowspan="2" colspan="1">P-value</th></tr><tr><th rowspan="1" colspan="1">(95% CI)</th><th rowspan="1" colspan="1">(95% CI)</th><th rowspan="1" colspan="1">(95% CI)</th><th rowspan="1" colspan="1">(95% CI)</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">DAS28-ESR</td><td rowspan="1" colspan="1">0.13 (&#x02212;0.20, 0.47)</td><td rowspan="1" colspan="1">0.438</td><td rowspan="1" colspan="1">0.06 (&#x02212;0.25, 0.38)</td><td rowspan="1" colspan="1">0.690</td><td rowspan="1" colspan="1">0.44 (0.07, 0.80)</td><td rowspan="1" colspan="1">&#x0003c;0.02</td><td rowspan="1" colspan="1">0.36 (0.02, 0.70)</td><td rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td rowspan="1" colspan="1">DAS28-CRP</td><td rowspan="1" colspan="1">&#x02212;0.05 (&#x02212;0.27, 0.18)</td><td rowspan="1" colspan="1">0.671</td><td rowspan="1" colspan="1">&#x02212;0.05 (&#x02212;0.27, 0.18)</td><td rowspan="1" colspan="1">0.685</td><td rowspan="1" colspan="1">0.17 (&#x02212;0.08, 0.41)</td><td rowspan="1" colspan="1">0.188</td><td rowspan="1" colspan="1">0.18 (&#x02212;0.07, 0.42)</td><td rowspan="1" colspan="1">0.163</td></tr><tr><td rowspan="1" colspan="1">Tender joint counts</td><td rowspan="1" colspan="1">0.07 (&#x02212;0.76, 0.91)</td><td rowspan="1" colspan="1">0.864</td><td rowspan="1" colspan="1">0.05 (&#x02212;0.78, 0.88)</td><td rowspan="1" colspan="1">0.911</td><td rowspan="1" colspan="1">1.34 (0.42, 2.25)</td><td rowspan="1" colspan="1">&#x0003c;0.01</td><td rowspan="1" colspan="1">1.32 (0.42, 2.22)</td><td rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td rowspan="1" colspan="1">Swollen joint counts</td><td rowspan="1" colspan="1">&#x02212;0.17 (&#x02212;0.71, 0.37)</td><td rowspan="1" colspan="1">0.530</td><td rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;0.74, 0.32)</td><td rowspan="1" colspan="1">0.438</td><td rowspan="1" colspan="1">0.97 (0.39, 1.56)</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.88 (0.30, 1.46)</td><td rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td rowspan="1" colspan="1">ESR</td><td rowspan="1" colspan="1">&#x02212;0.97 (&#x02212;5.06, 3.11)</td><td rowspan="1" colspan="1">0.641</td><td rowspan="1" colspan="1">&#x02212;1.07 (&#x02212;4.15, 2.00)</td><td rowspan="1" colspan="1">0.494</td><td rowspan="1" colspan="1">&#x02212;3.47 (&#x02212;7.89, 0.96)</td><td rowspan="1" colspan="1">0.124</td><td rowspan="1" colspan="1">&#x02212;3.87 (&#x02212;7.21, &#x02212;0.53)</td><td rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">&#x02212;2.60 (&#x02212;5.50, 0.30)</td><td rowspan="1" colspan="1">0.079</td><td rowspan="1" colspan="1">&#x02212;2.86 (&#x02212;5.67, &#x02212;0.05)</td><td rowspan="1" colspan="1">0.050</td><td rowspan="1" colspan="1">&#x02212;4.34 (&#x02212;7.49, &#x02212;1.18)</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#x02212;4.28 (&#x02212;7.34, &#x02212;1.21)</td><td rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td rowspan="1" colspan="1">Assessor global</td><td rowspan="1" colspan="1">0.86 (&#x02212;5.15, 6.86)</td><td rowspan="1" colspan="1">0.779</td><td rowspan="1" colspan="1">0.72 (&#x02212;5.30, 6.73)</td><td rowspan="1" colspan="1">0.815</td><td rowspan="1" colspan="1">5.23 (&#x02212;1.27, 11.73)</td><td rowspan="1" colspan="1">0.115</td><td rowspan="1" colspan="1">5.11 (&#x02212;1.40, 11.63)</td><td rowspan="1" colspan="1">0.124</td></tr><tr><td rowspan="1" colspan="1">Patient global</td><td rowspan="1" colspan="1">2.64 (&#x02212;3.32, 8.59)</td><td rowspan="1" colspan="1">0.385</td><td rowspan="1" colspan="1">3.00 (&#x02212;2.73, 8.74)</td><td rowspan="1" colspan="1">0.305</td><td rowspan="1" colspan="1">4.82 (&#x02212;1.62, 11.27)</td><td rowspan="1" colspan="1">0.142</td><td rowspan="1" colspan="1">5.34 (&#x02212;0.87, 11.55)</td><td rowspan="1" colspan="1">0.092</td></tr><tr><td rowspan="1" colspan="1">HAQ</td><td rowspan="1" colspan="1">0.04 (&#x02212;0.10, 0.17)</td><td rowspan="1" colspan="1">0.591</td><td rowspan="1" colspan="1">0.03 (&#x02212;0.10, 0.15)</td><td rowspan="1" colspan="1">0.690</td><td rowspan="1" colspan="1">0.15 (0.01, 0.30)</td><td rowspan="1" colspan="1">&#x0003c;0.05</td><td rowspan="1" colspan="1">0.13 (&#x02212;0.01, 0.27)</td><td rowspan="1" colspan="1">0.071</td></tr><tr><td rowspan="1" colspan="1">EQ5D-3L</td><td rowspan="1" colspan="1">&#x02212;0.04 (&#x02212;0.12, 0.03)</td><td rowspan="1" colspan="1">0.249</td><td rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.10, 0.04)</td><td rowspan="1" colspan="1">0.402</td><td rowspan="1" colspan="1">&#x02212;0.05 (&#x02212;0.13, 0.03)</td><td rowspan="1" colspan="1">0.248</td><td rowspan="1" colspan="1">&#x02212;0.04 (&#x02212;0.11,0.04)</td><td rowspan="1" colspan="1">0.326</td></tr><tr><td rowspan="1" colspan="1">VAS pain</td><td rowspan="1" colspan="1">6.62 (&#x02212;1.83, 15.06)</td><td rowspan="1" colspan="1">0.125</td><td rowspan="1" colspan="1">5.10 (&#x02212;2.49, 12.69)</td><td rowspan="1" colspan="1">0.188</td><td rowspan="1" colspan="1">3.85 (&#x02212;5.30, 12.99)</td><td rowspan="1" colspan="1">0.410</td><td rowspan="1" colspan="1">0.79 (&#x02212;7.55, 9.13)</td><td rowspan="1" colspan="1">0.853</td></tr><tr><td rowspan="1" colspan="1">FACIT fatigue</td><td rowspan="1" colspan="1">&#x02212;0.35 (&#x02212;2.93, 2.24)</td><td rowspan="1" colspan="1">0.793</td><td rowspan="1" colspan="1">&#x02212;0.58 (&#x02212;3.01, 1.85)</td><td rowspan="1" colspan="1">0.642</td><td rowspan="1" colspan="1">1.41 (&#x02212;1.38, 4.20)</td><td rowspan="1" colspan="1">0.321</td><td rowspan="1" colspan="1">1.03 (&#x02212;1.60, 3.65)</td><td rowspan="1" colspan="1">0.444</td></tr><tr><td rowspan="1" colspan="1">Larsen scores</td><td rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;1.69, 1.27)</td><td rowspan="1" colspan="1">0.780</td><td rowspan="1" colspan="1">0.13 (&#x02212;1.39, 1.64)</td><td rowspan="1" colspan="1">0.665</td><td rowspan="1" colspan="1">0.35 (&#x02212;1.25, 1.96)</td><td rowspan="1" colspan="1">0.867</td><td rowspan="1" colspan="1">0.63 (&#x02212;0.98, 2.25)</td><td rowspan="1" colspan="1">0.437</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><label>a</label><p>The model was adjusted for age at registration, gender and disease duration. EQ5D-3L: EuroQol 5-dimension scale; FACIT: Functional Assessment of Chronic Illness Therapy; VAS: visual analogue scale.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Impact of flares in proof of principle phase</title><p>The effects of flares, irrespective of treatment group, on 6-month outcomes were assessed in linear regression models adjusted for age, gender and disease duration. DAS28 scores were higher in patients who flared (0.85, 95% CI: 0.44, 1.26; P &#x0003c; 0.001) and EQ5D scores were lower (&#x02212;0.12, 95% CI: &#x02212;0.23, &#x02212;0.02; P = 0.022), but HAQ scores were unaffected (0.92, 95% CI: &#x02212;0.19, 0.22; P = 0.87).</p></sec><sec><title>Discontinuing TNF inhibitor</title><p>Thirty-four patients who tapered biologics in the proof of principle trial (21 with 33% tapering; 13 with 66% tapering) further tapered treatment until they stopped TNF inhibitor over 6 months in the exploratory study. Thirteen of thirty-four (38%) flared and 21/34 (62%) did not flare. Consequently 21/47 (45%) patients who started tapering in the proof of principle trial stopped TNF inhibitor by 12 months; 21/47 (45%) had flared and 5/47 (11%) had stopped tapering for other reasons. The 21 patients who stopped TNF inhibitor without flaring had initial DAS28 score of 1.51 (95% CI: 1.14, 2.65) and 12 month DAS28 scores of 2.27 (95% CI: 1.71, 3.98). Their initial HAQ was 0.65 (95% CI: 0.33, 0.99) and the 12 month HAQ 0.75 (95% CI: 0.42, 1.17).</p></sec><sec sec-type="subjects"><title>Flares in patient subgroups</title><p>The flare rate for patients receiving adalimumab, 18/54 (33%), was significantly lower (&#x003c7;<sup>2</sup> = 3.99, degrees of freedom (DF) = 1, P = 0.050) than for patients receiving etanercept, 23/43 (53%).</p><p>At baseline 74 patients were in remission and had DAS28 scores under 2.6; 27/74 (36%) of these patients flared. There were 23 patients with low disease activity (DAS28 score 2.6&#x02013;3.2) and 14/23 (61%) of these flared. The risk of flare was therefore significantly higher for patients with low disease activity at baseline (&#x003c7;<sup>2</sup> = 4.3, DF = 1, P = 0.039) than for those in remission.</p></sec><sec><title>Adverse events</title><p>Overall there were 443 adverse events; 76/97 (78%) patients had one or more events; 47/97 (48%) patients had an adverse event in the first 6 months and 29/89 (33%) in the second 6 months (<xref ref-type="table" rid="kex315-T4">Table 4</xref>); 4/97 (4%) of patients had a serious adverse event, 3 in the first 6 months and 1 in the second 6 months; 220/443 (50%) of adverse events involved the musculoskeletal system and only 223/443 (50%) involved other systems. No relationships were identified between treatment tapering and adverse events.
<table-wrap id="kex315-T4" orientation="portrait" position="float"><label>T<sc>able</sc> 4</label><caption><p>Serious and adverse events by body system and intervention group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead align="left"><tr><th rowspan="4" colspan="1">Body system</th><th colspan="6" align="center" rowspan="1">Proof of principle phase (0&#x02013;6 months)</th><th colspan="8" align="center" rowspan="1">Exploratory phase (6&#x02013;12 months)</th></tr><tr><th colspan="2" rowspan="2" align="center">Tapered 33%, n = 15 (96 episodes)</th><th colspan="2" rowspan="2" align="center">Tapered 66%, n = 13 (71 episodes)</th><th colspan="2" rowspan="2" align="center">Controls, n = 19 (120 episodes)</th><th colspan="2" rowspan="2" align="center">Tapering 33% until stop, n = 9 (54 episodes)</th><th colspan="2" rowspan="2" align="center">Tapering 66% until stop, n = 4 (28 episodes)</th><th colspan="4" align="center" rowspan="1">Re-randomized control group to</th></tr><tr><th colspan="2" align="center" rowspan="1">Tapered 33%, n = 10 (43 episodes)</th><th colspan="2" align="center" rowspan="1">Tapered 66%, n = 6 (35 episodes)</th></tr><tr><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th><th rowspan="1" colspan="1">Serious</th><th rowspan="1" colspan="1">All</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Cardiovascular</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Digestive</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">ENT</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">Endocrine/metabolic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Genitourinary</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Haematological</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Mental</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">Musculoskeletal</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">Nervous system</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Ophthalmological</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Respiratory</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">Skin</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p>Seventy-six patients had an adverse event; of those, 47 patients had an AE in the first 6 months and 29 in the next 6 months.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>OPTTIRA shows reducing TNF inhibitor doses by one-third in RA patients with stable low disease activity or remission also taking DMARDs has no impact on disease activity or the frequency of flares. However, the limited number of patients included in each arm restricts the importance of its finding for clinical practice. Most patients were in remission; there was some evidence patients with low disease activity scores had more flares. Greater reductions in TNF inhibitor doses led to more flares and higher disease activity levels but had no impact on disability. TNFi could be stopped in many patients without major negative impacts upon their disease.</p><p>The balance of evidence from OPTTIRA and previous trials and observational studies of tapering and stopping TNFi is that modest dose reduction is possible in RA patients with good responses to TNFi who remain on conventional DMARDs. Indeed there is little evidence favouring maintaining standard doses in such patients. OPTTIRA showed that reducing biologic doses by one-third had no impact on clinical, functional or health status assessments and did not result in more flares. TNFi are expensive with uncertainties about their overall cost-effectiveness [<xref rid="kex315-B26" ref-type="bibr">26</xref>, <xref rid="kex315-B27" ref-type="bibr">27</xref>] and in patients with good responses tapering appears less expensive than maintaining full doses without major negative impacts.</p><p>The evidence favouring major reductions in TNF inhibitor dose, such as reducing by two-thirds, is less clear-cut. OPTTIRA, other trials and observational studies all found this gives more flares and worse clinical and health status. However, the negative impacts are modest and in some patients treatment can be stopped without obvious disadvantages. Considering stopping treatment may be reasonable in selected cases.</p><p>Reductions in TNF inhibitor doses in stable RA have not been approved by regulatory agencies and therefore organizations like the National Institute for Health and Clinical Excellence cannot recommend such approaches [<xref rid="kex315-B28" ref-type="bibr">28</xref>]. Nevertheless, individual clinicians may decide, based on overall assessments of risks and benefits, to offer dose reductions to some patients. The impact of tapering TNFi is broadly similar to reducing the doses of conventional DMARDs; reducing MTX doses can be achieved in some patients but stopping treatment increases flares. Defining patients likely to flare is an important future research goal.</p><p>Adverse events were common in OPTTIRA and often involved the musculoskeletal system. Only four were serious events and these were unrelated to tapering or stopping treatment. The serious adverse event rate was similar to that in the systematic review of tapering by van Herwaarden <italic>et al.</italic> [<xref rid="kex315-B7" ref-type="bibr">7</xref>] who reported 5% of patients had serious adverse events. Such adverse event rates are likely to be commonplace in treated RA patients.</p><p>TNFi are expensive, and while using effective biosimilars [<xref rid="kex315-B29" ref-type="bibr">29</xref>] will reduce costs, such biologic treatments will never become inexpensive. Consequently the clinical and the economic benefits of good responders remaining on standard doses of TNFi will diverge. As the disadvantages of tapering and trying to stop TNFi are relatively small, clinicians and healthcare funders may consider it preferable to explore reducing and stopping treatment when patients achieve good disease control. In early RA, using biologics initially may result in sustained biologic-free and drug-free remissions [<xref rid="kex315-B30" ref-type="bibr">30</xref>, <xref rid="kex315-B31" ref-type="bibr">31</xref>]; OPTTIRA and similar trials have not evaluated this possibility. Nevertheless it may be important because achieving sustained deep remission may be of critical consequence in early disease.</p><p>Our trial had several strengths. It involved a range of RA patients across multiple English centres, making its findings likely to be generalizable. It evaluated two tapering regimens and stopping treatment, ensuring several strategies for reducing TNF inhibitor doses. It had several weaknesses. First, it was relatively small and enrolled only 97 patients. Its lack of power precludes robust conclusions in secondary analyses evaluating the impact of tapering on HAQ within the 66% tapering group. Secondly, it was relatively short and assessors were not blinded, in keeping with other pragmatic trials in the area. Thirdly, it did not look at all responders to TNFi, only those who had sustained low disease activity or remission; patients who almost achieved low disease activity may respond similarly to those enrolled in the trial. Fourthly, it only studied two TNFi, and may not apply to other TNFi. Fifthly, it did not consider sustained flares though there is some evidence [<xref rid="kex315-B32" ref-type="bibr">32</xref>] these are more important than transient flares, nor did it assess flares from patients&#x02019; perspectives, which recent research has highlighted as being relevant [<xref rid="kex315-B33" ref-type="bibr">33&#x02013;35</xref>]. Sixthly, many patients did not wish to participate in OPTTIRA; our non-participation rate was substantially higher than some trials like that reported by Moghadam <italic>et al.</italic> [<xref rid="kex315-B11" ref-type="bibr">11</xref>] but lower than others [<xref rid="kex315-B8" ref-type="bibr">8</xref>]. Similar high non-participation rates have occurred in other RA trials from our unit [<xref rid="kex315-B36" ref-type="bibr">36</xref>, <xref rid="kex315-B37" ref-type="bibr">37</xref>]. This difference may represent different ways of collecting data about screening or national differences in patients&#x02019; views on trials. However, caution is needed when considering our results&#x02019; generalizability. Finally, only limited information was available on radiological outcomes.</p><p>An issue in RA treatment, particularly relevant tapering biologics, is identifying patient sub-groups likely to respond well to the treatment strategy. Analysis of predictors in the BehandelStrategie&#x000eb;n (BeSt) trial [<xref rid="kex315-B38" ref-type="bibr">38</xref>] showed Anti-citrullinated protein antibody (ACPA) was an important indicator of flares after stopping infliximab. The impact of ACPA status on response to tapering was also reported by Haschka <italic>et al.</italic> [<xref rid="kex315-B10" ref-type="bibr">10</xref>]. More recently Rech <italic>et al.</italic> [<xref rid="kex315-B39" ref-type="bibr">39</xref>] showed combining ACPA status with multibiomarker disease activity assessment predicted relapses in over 80% of patients. An alternative is using US assessments to predict response to tapering [<xref rid="kex315-B40" ref-type="bibr">40</xref>, <xref rid="kex315-B41" ref-type="bibr">41</xref>]. There is evidence in our trial that tapering may be best in patients achieving deep remissions; further work is needed to clarify this possibility.</p><p>The most effective and cost-effective strategy for using biologics in RA patients remains uncertain. As current biologics are not curative in established RA patients, the rationale for their indefinite use in treatment responders is debatable. OPTTIRA shows modest tapering has no negative clinical impacts. We consider there is sufficient evidence for clinicians to reduce TNF inhibitor doses in some treatment responders. This approach may be more cost-effective than their continued use though it risks short-term disadvantages as flares are a burden to patients. Its impacts on disease status and healthcare costs need further evaluation, particularly as we found no evidence that tapering worsened patient-assessed outcomes.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>Supplementary Tables</label><media xlink:href="rhe-16-1831-file003_kex315.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sup2"><label>Supplementary Figure S1</label><media xlink:href="rhe-16-1831-file004_kex315.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We are grateful for the many colleagues and collaborators who contributed to the OPTTIRA trial. <italic>Trial Office Staff:</italic> Nestor Salazar, Amaka Ejibe, Rebecca Brendell, Dr Lisa Ann Clutterbuck, Dr Anna Kowalczyk, Beverley White-Alao, Janice Jimenez. <italic>Trial Steering Committee</italic>: Professor David G. I. Scott, Caroline J. Dor&#x000e9;, Dr Andrew Keat, Dr Brian Tom, Dr David Collins, Professor Simon Bowman, Ms Jacqui Deakin. <italic>Data Monitoring and Ethics Committee</italic>: Dr Chris Deighton (Chair), Dr Richard Watts, Professor Alex Macgregor. <italic>Principal Investigators</italic>: Dr Anurag Bharadwaj (Basildon University Hospital), Professor Andrew Cope (Guy&#x02019;s Hospital), Dr Ira Pande (Queens Medical Centre), Dr Sarah Levy (Croydon University Hospital), Dr David Walker (Freeman Hospital), Dr Michael Plant (James Cook University Hospital), Dr Stuart Kyle (North Devon Hospital), Dr Sarah Medley (Orpington Hospital), Dr Selwyn Richards (Poole Hospital), Dr Clive Kelly (Queen Elizabeth Gateshead Hospital), Dr Gerald Coakley (Queen Elizabeth Hospital, Woolwich) Dr Nap Cheung (Queen Mary&#x02019;s Hospital), Dr James Maxwell (Rotherham General Hospital), Professor Anthony Woolf (Royal Cornwall Hospital), Dr Richard Haigh (Royal Devon and Exeter Hospital), Dr Karen Walker-Bone (Royal Sussex County Hospital), Dr David Collins (The Great Western Hospital), Dr Kirsten Mackay (Torbay Hospital), Professor Gabrielle Kingsley (University Hospital Lewisham). Patient Involvement: Patients were involved in the design of the trial and a co-applicant on the grant. One this patient was on the trial steering committee throughout the trial.</p><p>
<italic>Funding</italic>: The trial was funded by Arthritis Research UK (grant reference number 18813).</p><p>
<italic>Disclosure statement</italic>: J.B.G. has received honoraria for speaking from UCB, Pfizer, Celgene and Bristol-Myers Squibb. All other authors have declared no conflicts of interest.</p><sec><title>Supplementary data</title><p>
<xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref> are available at <italic>Rheumatology</italic> Online.</p></sec></ack><ref-list><title>References</title><ref id="kex315-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>de La Forest Divonne</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gottenberg</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Salliot</surname><given-names>C.</given-names></name></person-group>
<article-title>Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers</article-title>. <source>Joint Bone Spine</source><year>2017</year>;<volume>84</volume>:<fpage>133</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">27341745</pub-id></mixed-citation></ref><ref id="kex315-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hazlewood</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Barnabe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tomlinson</surname><given-names>G</given-names></name></person-group>
<etal/>
<article-title>Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis</article-title>. <source>BMJ</source><year>2016</year>;<volume>353</volume>:<fpage>i1777</fpage>.<pub-id pub-id-type="pmid">27102806</pub-id></mixed-citation></ref><ref id="kex315-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Orme</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Macgilchrist</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Spurden</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>A.</given-names></name></person-group>
<article-title>Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70</article-title>. <source>Biologics</source><year>2012</year>;<volume>6</volume>:<fpage>429</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">23269860</pub-id></mixed-citation></ref><ref id="kex315-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Galvao</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Zimmermann</surname><given-names>IR</given-names></name>, <name name-style="western"><surname>da Mota</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Pereira</surname><given-names>MG.</given-names></name></person-group>
<article-title>Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis</article-title>. <source>Clin Rheumatol</source><year>2016</year>;<volume>35</volume>:<fpage>1659</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">27107756</pub-id></mixed-citation></ref><ref id="kex315-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kuijper</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Lamers-Karnebeek</surname><given-names>FBG</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>JWG</given-names></name>, <name name-style="western"><surname>Hazes</surname><given-names>JMW</given-names></name>, <name name-style="western"><surname>Luime</surname><given-names>JJ.</given-names></name></person-group>
<article-title>Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review</article-title>. <source>J Rheumatol</source><year>2015</year>;<volume>42</volume>:<fpage>2012</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">26428204</pub-id></mixed-citation></ref><ref id="kex315-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Navarro-Millan</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sattui</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>JR.</given-names></name></person-group>
<article-title>Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis</article-title>. <source>Clin Ther</source><year>2013</year>;<volume>35</volume>:<fpage>1850</fpage>&#x02013;<lpage>61.e1</lpage>.<pub-id pub-id-type="pmid">24156821</pub-id></mixed-citation></ref><ref id="kex315-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Herwaarden</surname><given-names>N</given-names></name>, <name name-style="western"><surname>den Broeder</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>W</given-names></name></person-group>
<etal/>
<article-title>Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity</article-title>. <source>Cochrane Database Syst Rev</source><year>2014</year>;(<volume>9</volume>):<fpage>CD010455</fpage>.</mixed-citation></ref><ref id="kex315-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chatzidionysiou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Turesson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Teleman</surname><given-names>A</given-names></name></person-group>
<etal/>
<article-title>A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission</article-title>. <source>RMD Open</source><year>2016</year>;<volume>2</volume>:<fpage>e000133</fpage>.<pub-id pub-id-type="pmid">26819752</pub-id></mixed-citation></ref><ref id="kex315-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fautrel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Alfaiate</surname><given-names>T</given-names></name></person-group>
<etal/>
<article-title>Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)</article-title>. <source>Ann Rheum Dis</source><year>2016</year>;<volume>75</volume>:<fpage>59</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">26103979</pub-id></mixed-citation></ref><ref id="kex315-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haschka</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Englbrecht</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hueber</surname><given-names>AJ</given-names></name></person-group>
<etal/>
<article-title>Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study</article-title>. <source>Ann Rheum Dis</source><year>2016</year>;<volume>75</volume>:<fpage>45</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25660991</pub-id></mixed-citation></ref><ref id="kex315-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Moghadam</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Vonkeman</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>ten Klooster</surname><given-names>PM</given-names></name></person-group>
<etal/>
<article-title>Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity</article-title>. <source>Arthritis Rheumatol</source><year>2016</year>;<volume>68</volume>:<fpage>1810</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26866428</pub-id></mixed-citation></ref><ref id="kex315-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Herwaarden</surname><given-names>N</given-names></name>, <name name-style="western"><surname>van der Maas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Minten</surname><given-names>MJ</given-names></name></person-group>
<etal/>
<article-title>Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial</article-title>. <source>BMJ</source><year>2015</year>;<volume>350</volume>:<fpage>h1389</fpage>.<pub-id pub-id-type="pmid">25858265</pub-id></mixed-citation></ref><ref id="kex315-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Vollenhoven</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Ostergaard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leirisalo-Repo</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source><year>2016</year>;<volume>75</volume>:<fpage>52</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25873634</pub-id></mixed-citation></ref><ref id="kex315-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yamanaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nagaoka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name></person-group>
<etal/>
<article-title>Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study</article-title>. <source>Mod Rheumatol</source><year>2016</year>;<volume>26</volume>:<fpage>651</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">26698929</pub-id></mixed-citation></ref><ref id="kex315-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hirata</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kubo</surname><given-names>S</given-names></name></person-group>
<etal/>
<article-title>Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study</article-title>. <source>Ann Rheum Dis</source><year>2015</year>;<volume>74</volume>:<fpage>389</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">24288014</pub-id></mixed-citation></ref><ref id="kex315-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kishimoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Radner</surname><given-names>H</given-names></name></person-group>
<etal/>
<article-title>Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry</article-title>. <source>Rheumatology</source><year>2016</year>;<volume>55</volume>:<fpage>286</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">26350484</pub-id></mixed-citation></ref><ref id="kex315-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Radner</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mjaavatten</surname><given-names>MD</given-names></name></person-group>
<etal/>
<article-title>Incidence and predictors of biological antirheumatic drug discontinuation attempts among patients with rheumatoid arthritis in remission: A CORRONA and NinJa Collaborative Cohort Study</article-title>. <source>J Rheumatol</source><year>2015</year>;<volume>42</volume>:<fpage>2238</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">26523025</pub-id></mixed-citation></ref><ref id="kex315-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schett</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Emery</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name></person-group>
<etal/>
<article-title>Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions</article-title>. <source>Ann Rheum Dis</source><year>2016</year>;<volume>75</volume>:<fpage>1428</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">27261493</pub-id></mixed-citation></ref><ref id="kex315-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Fautrel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Schulze-Koops</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Huizinga</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Kruger</surname><given-names>K.</given-names></name></person-group>
<article-title>Dosing down with biologic therapies: a systematic review and clinicians' perspective</article-title>. <source>Rheumatology</source><year>2017</year>;<volume>56</volume>:<fpage>1847</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28339632</pub-id></mixed-citation></ref><ref id="kex315-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Gestel</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Haagsma</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Riel</surname><given-names>PLCM.</given-names></name></person-group>
<article-title>Validation of rheumatoid arthritis improvement criteria that include simplified joint counts</article-title>. <source>Arthritis Rheum</source><year>1998</year>;<volume>41</volume>:<fpage>1845</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">9778226</pub-id></mixed-citation></ref><ref id="kex315-B21"><label>21</label><mixed-citation publication-type="other">
<collab>NICE</collab>. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. <year>2016</year>
<ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta375">https://www.nice.org.uk/guidance/ta375</ext-link>.</mixed-citation></ref><ref id="kex315-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van der Maas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lie</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Christensen</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study</article-title>. <source>Ann Rheum Dis</source><year>2013</year>;<volume>72</volume>:<fpage>1800</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">23178206</pub-id></mixed-citation></ref><ref id="kex315-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van der Heijde</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Klareskog</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Landewe</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source><year>2007</year>;<volume>56</volume>:<fpage>3928</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">18050208</pub-id></mixed-citation></ref><ref id="kex315-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van der Heijde</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Klareskog</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rodriguez-Valverde</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial</article-title>. <source>Arthritis Rheum</source><year>2006</year>;<volume>54</volume>:<fpage>1063</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">16572441</pub-id></mixed-citation></ref><ref id="kex315-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Silman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Symmons</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Griffiths</surname><given-names>I.</given-names></name></person-group>
<article-title>British Society for Rheumatology Biologics Register</article-title>. <source>Ann Rheum Dis</source><year>2003</year>;<volume>62(Suppl 2)</volume>:<fpage>ii28</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">14532144</pub-id></mixed-citation></ref><ref id="kex315-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Joensuu</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Huoponen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Aaltonen</surname><given-names>KJ</given-names></name></person-group>
<etal/>
<article-title>The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0119683</fpage>.<pub-id pub-id-type="pmid">25781999</pub-id></mixed-citation></ref><ref id="kex315-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stevenson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Archer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tosh</surname><given-names>J</given-names></name></person-group>
<etal/>
<article-title>Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation</article-title>. <source>Health Technol Assess</source><year>2016</year>;<volume>20</volume>:<fpage>1</fpage>&#x02013;<lpage>610</lpage>.</mixed-citation></ref><ref id="kex315-B28"><label>28</label><mixed-citation publication-type="other">
<collab>NICE</collab>. Guide to the Processes of Technology Appraisal (PMG19). <year>2014</year>
<ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/process/pmg19">www.nice.org.uk/process/pmg19</ext-link> (date last accessed, 19 June 2017).</mixed-citation></ref><ref id="kex315-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chingcuanco</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Segal</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>GC.</given-names></name></person-group>
<article-title>Bioequivalence of biosimilar tumor necrosis factor-alpha inhibitors compared with their reference biologics a systematic review</article-title>. <source>Ann Intern Med</source><year>2016</year>;<volume>165</volume>:<fpage>565</fpage>.<pub-id pub-id-type="pmid">27479870</pub-id></mixed-citation></ref><ref id="kex315-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Smolen</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Emery</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Fleischmann</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial</article-title>. <source>Lancet</source><year>2014</year>;<volume>383</volume>:<fpage>321</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">24168956</pub-id></mixed-citation></ref><ref id="kex315-B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bijlsma</surname><given-names>JWJ</given-names></name>, <name name-style="western"><surname>Welsing</surname><given-names>PMJ</given-names></name>, <name name-style="western"><surname>Woodworth</surname><given-names>TG</given-names></name></person-group>
<etal/>
<article-title>Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial</article-title>. <source>Lancet</source><year>2016</year>;<volume>388</volume>:<fpage>343</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27287832</pub-id></mixed-citation></ref><ref id="kex315-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Myasoedova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Chandran</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ilhan</surname><given-names>B</given-names></name></person-group>
<etal/>
<article-title>The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease</article-title>. <source>Ann Rheum Dis</source><year>2016</year>;<volume>75</volume>:<fpage>560</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25637001</pub-id></mixed-citation></ref><ref id="kex315-B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Bykerk</surname><given-names>VP</given-names></name>, <name name-style="western"><surname>Cooksey</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: report of the OMERACT 2014 RA Flare Group Plenary</article-title>. <source>J Rheumatol</source><year>2015</year>;<volume>42</volume>:<fpage>2185</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25684764</pub-id></mixed-citation></ref><ref id="kex315-B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bingham</surname><given-names>CO</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Pohl</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Woodworth</surname><given-names>TG</given-names></name></person-group>
<etal/>
<article-title>Developing a standardized definition for disease &#x0201c;flare&#x0201d; in rheumatoid arthritis (OMERACT 9 Special Interest Group)</article-title>. <source>J Rheumatol</source><year>2009</year>;<volume>36</volume>:<fpage>2335</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">19684147</pub-id></mixed-citation></ref><ref id="kex315-B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fautrel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Morel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Berthelot</surname><given-names>JM</given-names></name></person-group>
<etal/>
<article-title>Validation of FLARE-RA, a self-administered tool to detect recent or current rheumatoid arthritis flare</article-title>. <source>Arthritis Rheumatol</source><year>2017</year>;<volume>69</volume>:<fpage>309</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">27636400</pub-id></mixed-citation></ref><ref id="kex315-B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Choy</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Farewell</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source><year>2008</year>;<volume>67</volume>:<fpage>656</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">17768173</pub-id></mixed-citation></ref><ref id="kex315-B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Farewell</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial</article-title>. <source>BMJ</source><year>2015</year>;<volume>350</volume>:<fpage>h1046</fpage>.<pub-id pub-id-type="pmid">25769495</pub-id></mixed-citation></ref><ref id="kex315-B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Klarenbeek</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>van der Kooij</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Guler-Yuksel</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study</article-title>. <source>Ann Rheum Dis</source><year>2011</year>;<volume>70</volume>:<fpage>315</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21068104</pub-id></mixed-citation></ref><ref id="kex315-B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rech</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hueber</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Finzel</surname><given-names>S</given-names></name></person-group>
<etal/>
<article-title>Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment</article-title>. <source>Ann Rheum Dis</source><year>2016</year>;<volume>75</volume>:<fpage>1637</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">26483255</pub-id></mixed-citation></ref><ref id="kex315-B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Alivernini</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peluso</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fedele</surname><given-names>AL</given-names></name></person-group>
<etal/>
<article-title>Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission</article-title>. <source>Arthritis Res Therapy</source><year>2016</year>;<volume>18</volume>:<fpage>39</fpage>.</mixed-citation></ref><ref id="kex315-B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Naredo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Valor</surname><given-names>L</given-names></name>, <name name-style="western"><surname>De la Torre</surname><given-names>I</given-names></name></person-group>
<etal/>
<article-title>Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis</article-title>. <source>Rheumatology</source><year>2015</year>;<volume>54</volume>:<fpage>1408</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">25731769</pub-id></mixed-citation></ref></ref-list></back></article>